Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short term Debt (2016 - 2023)

Historic Short term Debt for Amicus Therapeutics (FOLD) over the last 14 years, with Q2 2023 value amounting to $13.0 million.

  • Amicus Therapeutics' Short term Debt fell 3249.77% to $13.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $13.0 million, marking a year-over-year decrease of 3249.77%. This contributed to the annual value of $21.4 million for FY2022, which is 1331.75% up from last year.
  • As of Q2 2023, Amicus Therapeutics' Short term Debt stood at $13.0 million, which was down 3249.77% from $12.7 million recorded in Q1 2023.
  • Amicus Therapeutics' Short term Debt's 5-year high stood at $21.4 million during Q4 2022, with a 5-year trough of $8.9 million in Q4 2020.
  • For the 4-year period, Amicus Therapeutics' Short term Debt averaged around $17.2 million, with its median value being $19.2 million (2022).
  • Per our database at Business Quant, Amicus Therapeutics' Short term Debt skyrocketed by 11235.96% in 2021 and then tumbled by 3385.2% in 2023.
  • Over the past 4 years, Amicus Therapeutics' Short term Debt (Quarter) stood at $8.9 million in 2020, then soared by 112.36% to $18.9 million in 2021, then grew by 13.32% to $21.4 million in 2022, then tumbled by 39.28% to $13.0 million in 2023.
  • Its Short term Debt was $13.0 million in Q2 2023, compared to $12.7 million in Q1 2023 and $21.4 million in Q4 2022.